Vernon Hills, IL, United States of America

Alan Frank Gasiecki

This inventor holds 29 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: G.d. Searle & Company, Abbvie Inc., Pharmacia Corporation. Active years: 1985-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alan Frank Gasiecki. Retrieved from https://idiyas.com/inventor/alan-frank-gasiecki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 1)

% Patents Active = 75.9

CIPO Patents = 3 (Patent Applications = 10)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 4.5

ph-index = 9

Forward Citations = 307(Granted Patents)

Company Filing History:

18 out of 1,323

G.d. Searle & Company

Pharmacia Corporation

patents

4. 3 out of 167

Abbvie Deutschland Gmbh and Co Kg

patents

5. 1 out of 4,188

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 1985-2018

Loading Chart...

Areas of Expertise:

5-HT Receptors

Kinase Inhibitors

Integrin Receptor Antagonists

Prostaglandins

Protease Inhibitors

Heterocyclic Derivatives

Phenylene Sulphonamide

Hydrolase Inhibitors

Cycloalkyl Acids

Tetraenyl Derivatives

Pharmaceutical Compositions

Omega Cycloalkyl

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9879033 - Modulators of 5-HT receptors and methods of use thereof (2018-01-30),

2. 9187483 - Modulators of 5-HT receptors and methods of use thereof (2015-11-17),

3. 9163007 - 5-substituted indazoles as kinase inhibitors (2015-10-20),

4. 8846951 - Modulators of 5-HT receptors and methods of use thereof (2014-09-30),

5. 8648069 - 5-substituted indazoles as kinase inhibitors (2014-02-11),

6. 7468371 - Tricyclic pyrazole kinase inhibitors (2008-12-23),

7. 7119203 - Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors (2006-10-10),

8. 6949578 - Cycloalkyl alkanoic acids as integrin receptor antagonists (2005-09-27),

9. 6921767 - Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives (2005-07-26),

10. 6900232 - Cycloalkyl alkanoic acids as integrin receptor antagonists (2005-05-31),

11. 6689754 - Heterocyclic glycyl &bgr;-alanine derivatives (2004-02-10),

12. 6677308 - Meta-substituted phenylene sulphonamide derivatives (2004-01-13),

13. 6531494 - Gem-substituted &agr;v&bgr;3 antagonists (2003-03-11),

14. 6506876 - LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use (2003-01-14),

15. 5843906 - Meta-substituted phenylene sulphonamide derivatives (1998-12-01),

Title: Unveiling the Innovations of Alan Frank Gasiecki

Introduction:

Alan Frank Gasiecki, a prolific inventor based in Vernon Hills, IL (US), has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 29 patents. His groundbreaking work has focused on modulators of 5-HT receptors and their therapeutic applications.

Latest Patents:

Gasiecki's latest patents revolve around aryl- and heteroaryl-fused compounds, specifically decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives. These compounds exhibit potential in treating various disease conditions, emphasizing their role as innovative pharmaceutical agents.

Career Highlights:

Having worked in esteemed companies such as G.D. Searle & Company and AbbVie Inc., Gasiecki has honed his skills and expertise in the pharmaceutical industry. His inventive spirit and dedication have led to the development of novel therapeutic solutions, earning him recognition as a key figure in the field of pharmaceutical innovations.

Collaborations:

Throughout his career, Gasiecki has collaborated with notable professionals in the industry, including Mark Andrew Russell and Michael John Clare. These collaborations have not only enriched his work but have also fostered a culture of innovation and teamwork, leading to the successful development of groundbreaking pharmaceutical technologies.

Conclusion:

In conclusion, Alan Frank Gasiecki stands as a pioneering figure in the realm of pharmaceutical innovations. His relentless pursuit of novel solutions and unwavering commitment to advancing healthcare through inventive technologies underscore his significant contributions to the field. Gasiecki's patents and collaborations serve as a testament to his passion for innovation and his enduring impact on the pharmaceutical landscape.

Profile summary based on public USPTO records.